Account Options

  1. Sign in
    Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

    Patents

    1. Advanced Patent Search
    Publication numberWO2005096704 B1
    Publication typeApplication
    Application numberPCT/IB2005/000929
    Publication date4 May 2006
    Filing date8 Apr 2005
    Priority date8 Apr 2004
    Also published asUS20050227930, WO2005096704A2, WO2005096704A3
    Publication numberPCT/2005/929, PCT/IB/2005/000929, PCT/IB/2005/00929, PCT/IB/5/000929, PCT/IB/5/00929, PCT/IB2005/000929, PCT/IB2005/00929, PCT/IB2005000929, PCT/IB200500929, PCT/IB5/000929, PCT/IB5/00929, PCT/IB5000929, PCT/IB500929, WO 2005/096704 B1, WO 2005096704 B1, WO 2005096704B1, WO-B1-2005096704, WO2005/096704B1, WO2005096704 B1, WO2005096704B1
    InventorsNajla Guthrie
    ApplicantKgk Synergize Inc, Najla Guthrie
    Export CitationBiBTeX, EndNote, RefMan
    Classifications (11), Legal Events (7)
    External Links: Patentscope, Espacenet
    Cholesterol lowering composition
    WO 2005096704 B1
    Abstract
    Compositions and methods for the treatment for the prevention and treatment of hypercholesterolemia and atherosclerosis are described. Individuals at a high risk of developing or having hypercholesterolemia and atherosclerosis may be treated with an effective dose of a composition comprising at least one citrus flavonoid, at least one tocotrienol, and at least one phytosterol or phytosterol ester.
    Amended Claims  (OCR text may contain errors)
    AMENDED CLAIMS
    [received by the International Bureau on 25 November 2005 (25/11/05) original claims 1-7 replaced by new claims 1-7 (1 page)]
    THE EMBODIMENTS OF THE INVENTION IN .WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
    1 A pharmaceutical composition for lowering cholesterol in mammals, the composition comprising a cholesterol lowering amount of:
    -at least one citrus flavonoid;.
    -at least one phytosterol or phytosterol ester; and
    -at least one tocotrienol.
    2. The pharmaceutical composition according to claim 1 wherein said at least one flavonoid is selected from one or more flavonoids of the group consisting of hesparidin, naringin, naringenin, hesperetin, nobiletin and tangeretin.
    3. The pharmaceutical composition according to claim 1 wherein said at least one tocotrienol is selected from one or more tocotrienols of the groups consisting of alpha- tocotrienol, gamma-tocotrienol and delta-tocotrienol.
    4. The pharmaceutical composition according to claim 1 further comprising at least one pharmaceutically acceptable adjuvant.
    5. The pharmaceutical composition.of claim 4 wherein said at least one pharmaceutically acceptable adjuvant is selected from the group consisting of diluents, stabilizers, binders, buffers, lubricants, coating agents, preservatives, emulsifiers, and suspension agents.
    6. A method of treating hypercholesterolemia or atherosclerosis in a mammal, said method comprising administration of the pharmaceutical composition according to anyone of claims 1 to 5 to said mammal.
    7. The method according to claim 6 wherein said administration is intravenous, intraperitoneally, subcutaneous, intramuscular, oral, rectal, topical or aerosol.
    AMENDED SHEET (ARTICLE 19)
    Classifications
    International ClassificationA61K31/355, A61K31/56, A61K31/7048, A61K31/353
    Cooperative ClassificationA61K31/355, A61K31/7048, A61K31/56
    European ClassificationA61K31/56, A61K31/353, A61K31/355, A61K31/7048
    Legal Events
    DateCodeEventDescription
    20 Oct 2005ALDesignated countries for regional patents
    Kind code of ref document: A2
    Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
    20 Oct 2005AKDesignated states
    Kind code of ref document: A2
    Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
    4 May 2006BLater publication of amended claims
    Effective date: 20051125
    10 Oct 2006NENPNon-entry into the national phase in:
    Ref country code: DE
    10 Oct 2006WWWWipo information: withdrawn in national office
    Country of ref document: DE
    2 May 200732PNEp: public notification in the ep bulletin as address of the adressee cannot be established
    Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO COMMUNICATIONS FORMS: 1205A DATED: 20.12.2006 & 29.01.2007)
    19 Sep 2007122Ep: pct app. not ent. europ. phase